Cimeio: Cimeio signs $300 million agreement with Japanese pharma company

Founded as a spin-off of the University of Basel, Cimeio Therapeutics focusing on the development of novel immunotherapies for the treatment of hematologic diseases, has signed a significant collaboration agreement with Japanese Pharma, Kyowa Kirin to accelerate cell therapies into the clinical phase. Among other terms, the startup is eligible to receive up to CHF 263 million ($300M).